These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38997087)

  • 1. A quadrivalent norovirus vaccine based on a chimpanzee adenovirus vector induces potent immunity in mice.
    Jiang Y; Sun L; Qiao N; Wang X; Zhu C; Xing M; Liu H; Zhou P; Zhou D
    Virol Sin; 2024 Aug; 39(4):675-684. PubMed ID: 38997087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial.
    Lindesmith LC; Ferris MT; Mullan CW; Ferreira J; Debbink K; Swanstrom J; Richardson C; Goodwin RR; Baehner F; Mendelman PM; Bargatze RF; Baric RS
    PLoS Med; 2015 Mar; 12(3):e1001807. PubMed ID: 25803642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes.
    Malm M; Tamminen K; Heinimäki S; Vesikari T; Blazevic V
    Vaccine; 2018 Jan; 36(4):484-490. PubMed ID: 29246474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal P particle vaccine provided partial cross-variant protection against human GII.4 norovirus diarrhea in gnotobiotic pigs.
    Kocher J; Bui T; Giri-Rachman E; Wen K; Li G; Yang X; Liu F; Tan M; Xia M; Zhong W; Jiang X; Yuan L
    J Virol; 2014 Sep; 88(17):9728-43. PubMed ID: 24920797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous Immunization with Multivalent Norovirus VLPs Induces Better Protective Immune Responses to Norovirus Than Sequential Immunization.
    Malm M; Vesikari T; Blazevic V
    Viruses; 2019 Nov; 11(11):. PubMed ID: 31684058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 6-Valent Virus-Like Particle-Based Vaccine Induced Potent and Sustained Immunity Against Noroviruses in Mice.
    Hou W; Lv L; Wang Y; Xing M; Guo Y; Xie D; Wei X; Zhang X; Liu H; Ren J; Zhou D
    Front Immunol; 2022; 13():906275. PubMed ID: 35711416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition.
    Malm M; Tamminen K; Lappalainen S; Uusi-Kerttula H; Vesikari T; Blazevic V
    Clin Vaccine Immunol; 2015 Jun; 22(6):656-63. PubMed ID: 25903355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice.
    Tamminen K; Lappalainen S; Huhti L; Vesikari T; Blazevic V
    PLoS One; 2013; 8(7):e70409. PubMed ID: 23922988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B-Cell Responses to Intramuscular Administration of a Bivalent Virus-Like Particle Human Norovirus Vaccine.
    Ramani S; Neill FH; Ferreira J; Treanor JJ; Frey SE; Topham DJ; Goodwin RR; Borkowski A; Baehner F; Mendelman PM; Estes MK; Atmar RL
    Clin Vaccine Immunol; 2017 May; 24(5):. PubMed ID: 28249841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine.
    Leroux-Roels I; Maes C; Joye J; Jacobs B; Jarczowski F; Diessner A; Janssens Y; Waerlop G; Tamminen K; Heinimäki S; Blazevic V; Leroux-Roels G; Klimyuk V; Adachi H; Hiruta K; Thieme F
    Front Immunol; 2022; 13():1021500. PubMed ID: 36275772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Norovirus GII.17 Virus-Like Particles Bind to Different Histo-Blood Group Antigens and Cross-React with Genogroup II-Specific Mouse Sera.
    Malm M; Tamminen K; Vesikari T; Blazevic V
    Viral Immunol; 2018 Dec; 31(10):649-657. PubMed ID: 30431404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations.
    Parra GI; Bok K; Taylor R; Haynes JR; Sosnovtsev SV; Richardson C; Green KY
    Vaccine; 2012 May; 30(24):3580-6. PubMed ID: 22469864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type-specific and cross-reactive antibodies and T cell responses in norovirus VLP immunized mice are targeted both to conserved and variable domains of capsid VP1 protein.
    Malm M; Tamminen K; Vesikari T; Blazevic V
    Mol Immunol; 2016 Oct; 78():27-37. PubMed ID: 27573255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of immunogenicity of norovirus GII-4 virus-like particles and P-particles.
    Tamminen K; Huhti L; Koho T; Lappalainen S; Hytönen VP; Vesikari T; Blazevic V
    Immunology; 2012 Jan; 135(1):89-99. PubMed ID: 22044070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal Antibodies Induced by Intranasal but Not Intramuscular Immunization Block Norovirus GII.4 Virus-Like Particle Receptor Binding.
    Tamminen K; Malm M; Vesikari T; Blazevic V
    Viral Immunol; 2016 Jun; 29(5):315-9. PubMed ID: 27135874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of three virus-derived nanoparticles as a vaccine against enteric pathogens; enterovirus, norovirus and rotavirus.
    Heinimäki S; Hankaniemi MM; Sioofy-Khojine AB; Laitinen OH; Hyöty H; Hytönen VP; Vesikari T; Blazevic V
    Vaccine; 2019 Dec; 37(51):7509-7518. PubMed ID: 31585726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine.
    Blazevic V; Malm M; Arinobu D; Lappalainen S; Vesikari T
    Hum Vaccin Immunother; 2016 Mar; 12(3):740-8. PubMed ID: 26467630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human Sera Collected between 1979 and 2010 Possess Blocking-Antibody Titers to Pandemic GII.4 Noroviruses Isolated over Three Decades.
    Sharma S; Carlsson B; Czakó R; Vene S; Haglund M; Ludvigsson J; Larson G; Hammarström L; Sosnovtsev SV; Atmar RL; Green KY; Estes MK; Svensson L
    J Virol; 2017 Jul; 91(14):. PubMed ID: 28468886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological and immunological characterization of norovirus major capsid proteins from three different genotypes.
    Huo Y; Wan X; Ling T; Shen S
    Microb Pathog; 2016 Jan; 90():78-83. PubMed ID: 26616166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic and antigenic diversity among noroviruses.
    Hansman GS; Natori K; Shirato-Horikoshi H; Ogawa S; Oka T; Katayama K; Tanaka T; Miyoshi T; Sakae K; Kobayashi S; Shinohara M; Uchida K; Sakurai N; Shinozaki K; Okada M; Seto Y; Kamata K; Nagata N; Tanaka K; Miyamura T; Takeda N
    J Gen Virol; 2006 Apr; 87(Pt 4):909-919. PubMed ID: 16528040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.